Unlocking the power of machine learning for small molecule drug discovery
Rick Wagner of ZebiAI and Patrick Riley of Google Accelerated Science (GAS) discuss the development and benefits of a new machine learning drug discovery platform.
List view / Grid view
Rick Wagner of ZebiAI and Patrick Riley of Google Accelerated Science (GAS) discuss the development and benefits of a new machine learning drug discovery platform.
26 June 2020 | By Tecan
This webinar described the recent efforts to identify small molecule therapeutics for the treatment of SARS-CoV-2 infection and COVID-19 disease.
Researchers have developed a video and model-building programme for other scientists to build full-length COVID-19 S protein models.
An artificial intelligence platform available online has been designed to help researchers track the genetics of SARS-CoV-2 as it moves from person to person.
An area where stem cell biology and medicine are combining effectively is the establishment of new cell therapies. However, current therapies are limited to a narrow set of cell types that can be isolated or created and expanded in vitro. Dr Owen Rackham discusses how utilising computational approaches will further…
The latest generation of three-dimensional (3D) cell models offer new and exciting possibilities for pharmaceutical research. However, deciding how to capture sufficient information in the most efficient way from an experiment without making the data size overwhelming can prove challenging. Margaritha Mysior and Jeremy Simpson discuss the opportunities and challenges…
The 3D map, created using Knife-Edge Scanning Microscopy and analysed using laser capture microdissection, reveals new insights about the nervous control of the heart.
Exploring large databases and selecting compounds of interest can be extremely time-consuming for researchers. Here, Sacha Javor, Horst Flotow and Jingwen Shi discuss a novel chemoinformatics approach for drug discovery.
The Genome Aggregation Database (gnomAD) Consortium has released seven papers leveraging its database to study genetic variants and their potential for guiding discovery of safer drugs.
Collaboration between scientists, illustrators and simulators has culminated in highly detailed three-dimensional (3D) models of SARS-CoV-2.
Scientists have designed a high affinity antibody for pathogenic amyloid beta oligomers, a key driver of Alzheimer’s disease, for use in further research and as a potential diagnostic tool.
The stem cells in-depth focus includes articles on using computational approaches to expand the applications of stem cell therapies and how organoids could be used to speed up the drug discovery process with a focus on retinal disease.
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
Scientists have developed a method for designing artificial proteins that tell the immune system which antibodies to produce so could enhance vaccine design.
Researchers are utilising computers to aid in their investigations into a COVID-19 treatment. Here, we highlight three studies using simulations, calculations and AI to identify a drug to combat the coronavirus.